Compared to the Tpex‐only adoptive cellular therapy group, the proportion of CD45.2+CD8+ T cells infiltrating the tumor was significantly higher in the Tpex plus CX4945 group (Figure S4G,H, Supporting Information). The gene discussed is CD8A; the disease is neoplasm.